Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers

Author： Saif M Wasif   Tytler Ewan   Lansigan Frederick   Brown David M   Husband Alan J  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.4, 2009-04, pp. : 469-479

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

By Pescatore S.L.   Lindley C.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 537-546

Informa Healthcare

Access to resources Recommend Favorite

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers

By Kindler Hedy   Tothy Peter   Wolff Robert   McCormack Richard   Abbruzzese James   Mani Sridhar   Wade-Oliver Kurombi   Vokes Everett  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 489-493

Springer Publishing Company

Access to resources Recommend Favorite

NaI symporter could provide novel treatment strategy for cancers

By  

Inpharma, Vol. 1, Iss. 1378, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages

By Ceccarelli Simona   Romano Ferdinando   Angeloni Antonio   Marchese Cinzia  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 377-393

Informa Healthcare

Access to resources Recommend Favorite

Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers

By  

Current Drug Targets, Vol. 12, Iss. 14, 2011-12 ,pp. : 2016-2033

Bentham Science Publishers

Access to resources Recommend Favorite